The research group of Bacterial infections: antimicrobial therapies from the Institute for Bioengineering of Catalonia (IBEC) in Barcelona Science Park has revealed the essential role played by a vitamin in the development of a common bacterial biofilm. This new knowledge could play a part in understanding the spread of these bacteria, which will help towards the better design of targeted antibacterial drugs.
Laboratorios Ordesa head up the TOLERA consortium, which was conceived with the aim of developing workable solutions for the food industry that provide safer and more effective foodstuffs and ingredients to prevent people from developing food intolerances and allergies. Under the framework of this project—driven by the Centre for the Development of Industrial Technology (CDTI) with a budget of €8.1 million for the 2018-2021 period—the company will promote various research studies, both their own at their research centre in Barcelona Science Park, and in partnership with other companies, universities and public and private R&D centres.
One more year, the Barcelona Science Park (PCB) participates in BIO International Convention, the largest global event for the biotech and pharmaceutical sector hosted annually by the Biotechnology Industry Organization (BIO). This year the meeting will take place from 4 to 7 June in Boston (Massachusetts, United States) and is expected to attract more than 16,000 attendees from 74 countries. The Catalan delegation makes up half of all of the Spanish companies participating in the fair, with 38 companies and organizations, nine of which are based in PCB.
The research group of ICREA professor Xavier Trepat at IBEC in PCB revelals that cell division in epithelial tissues is regulated by mechanical forces Thie study, published in Nature Cell Biology, could potentially opening avenues to a greater understanding of the uncontrolled proliferation of cancer cells in tumors, and their possible regulation by means of physical forces.
A study conducted at IRB Barcelona in Barcelona Science Park, published today in the journal Cancer Cell, rreveals a new protective mechanism for tumour cells in breast cancer and identifies novel therapeutic targets to treat this condition. The paper identifies the key role of p38 in safeguarding tumour cells against the excessive accumulation of DNA damage. The results show that p38 blockage ncreases the death of tumour cells, thus causing tumours to shrink.
The Academy of Medical Sciences and Health of Catalonia and the Balearic Islands Foundation has recognised Doctor Martí Manyalich –president of the DTI (Donation & Transplantation Institute) Foundation, located in the Barcelona Science Park (PCB) –with the Josep Trueta prize for scientific research. The prize awarding ceremony took place yesterday with the other Academy’s awards.
An article published in Cell Chemical Biology by scientists at the Institute for Research in Biomedicine (IRB Barcelona) in Barcelona Science Park (PCB) describes a new class of prolyl oligopeptidase (POP) inhibitors. Found mostly in the brain, POP protein has emerged as an “attractive·” therapeutic target for the treatment of several cognitive and neurodegenerative disorders, such as Parkinson’s disease and schizophrenia.The work was done in collaboration with the biotech Iproteos, based in PCB and scientists at the University of Glasgow (Scotland, UK) and the Utrecht Institute for Pharmaceutical Sciences (the Netherlands). The study has also involved the Nuclear Magnetic Resonance Laboratory (LRB) –wich is part of CCiTUB and it’s located in the Cluster building of the Park– and the Barcelona Supercomputing Center (BSC).
World MS Day will be held on Wednesday 30 May. This year’s campaign is called Bringing Us Closer and the theme is research. GAEM Foundation, based in Barcelona Science Park, wants to participate actively in this international campaign by organizing a series of activities to raise awareness of the need to join forces and continue to promote research to find a cure for this disease as soon as possible.
The Scientific and Technological Centers of the University of Barcelona (CCiTUB) reached their first thirty years of activity over which they have become widely known in both the national and international fields of research, innovation, and transfer. At the moment, the team in CCiTUB is formed by a hundred and sixty experts and administration staff, and eighty of tem are doctors, distributed in thirty-eight units, six of which are located in the Barcelona Science Park (PCB), among which there is the Nuclear Magnetic Resonance Laboratory (LRB), listed in the Map of Unique Scientific and Technical Infraestructures (ICTS).
Bionure, a biotech company based in the Barcelona Science Park that develops neuroprotectant agents to treat neurodegenerative diseases primarily focusing on rare ophthalmologic diseases, announces today the initiation of a Phase 1 clinical trial of its lead compound BN201 in the United Kingd. BN201 is a first-in-class treatment that promotes remyelination and neuroprotection, offering a game-changing solution for neurodegenerative diseases. Both actions make BN201 a promising solution for rare ophthalmologic diseases and open a research pathway to treat other neurodegenerative diseases such as Multiple Sclerosis (MS).
